drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Gene-modified autologous T cells engineered to express a chimeric antigen receptor that recognizes VEGFR1 and PD-L1; upon antigen engagement, the CAR T cells exert cytotoxic activity against VEGFR1+ and/or PD-L1+ cells, aiming to disrupt VEGF/VEGFR1-driven angiogenesis and overcome PD-L1–mediated immune suppression. Administered regionally into the pleural or peritoneal cavity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intrapleural, Intraperitoneal
drug_mechanism_of_action
Autologous T cells genetically engineered to express a chimeric antigen receptor recognizing VEGFR1 and PD-L1. Binding to either antigen triggers T‑cell activation, cytotoxicity, and cytokine release to kill VEGFR1+ vascular/endothelial cells and PD‑L1+ tumor and immunosuppressive stromal/immune cells, disrupting VEGF/VEGFR1‑driven angiogenesis and overcoming PD‑L1–mediated immune evasion. Administered regionally into the pleural or peritoneal cavity.
drug_name
Dual-targeting VEGFR1/PD-L1 CAR-T cells
nct_id_drug_ref
NCT05477927